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Modulation of TGF-beta activity by latent TGF-beta-binding
protein 1 in human malignant glioma cells
Abstract
High biological activity of the transforming growth factor (TGF)-beta-Smad pathway characterizes the
malignant phenotype of malignant gliomas and confers poor prognosis to glioma patients. Accordingly,
TGF-beta has become a novel target for the experimental treatment of these tumors. TGF-beta is
processed by furin-like proteases (FLP) and secreted from cells in a latent complex with its processed
propeptide, the latency-associated peptide (LAP). Latent TGF-beta-binding protein 1 (LTBP-1)
covalently binds to this small latent TGF-beta complex (SLC) and regulates its function, presumably via
interaction with the extracellular matrix (ECM). We report here that the levels of LTBP-1 protein in
vivo increase with the grade of malignancy in gliomas. LTBP-1 is associated with the ECM as well as
secreted into the medium in cultured malignant glioma cells. The release of LTBP-1 into the medium is
decreased by the inhibition of FLP activity. Gene-transfer mediated overexpression of LTBP-1 in
glioma cell lines results in an increase inTGF-beta activity. Accordingly, Smad2 phosphorylation as an
intracellular marker of TGF-beta activity is enhanced. Conversely, LTBP-1 gene silencing reduces
TGF-beta activity and Smad2 phosphorylation without affecting TGF-beta protein levels. Collectively,
we identify LTBP-1 as an important modulator of TGF-beta activation in glioma cells, which may
contribute to the malignant phenotype of these tumors.
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High biological activity of the transforming growth factor (TGF)-
b-Smad pathway characterizes the malignant phenotype of malig-
nant gliomas and confers poor prognosis to glioma patients.
Accordingly, TGF-b has become a novel target for the experimen-
tal treatment of these tumors. TGF-b is processed by furin-like
proteases (FLP) and secreted from cells in a latent complex with
its processed propeptide, the latency-associated peptide (LAP).
Latent TGF-b-binding protein 1 (LTBP-1) covalently binds to this
small latent TGF-b complex (SLC) and regulates its function, pre-
sumably via interaction with the extracellular matrix (ECM). We
report here that the levels of LTBP-1 protein in vivo increase with
the grade of malignancy in gliomas. LTBP-1 is associated with the
ECM as well as secreted into the medium in cultured malignant
glioma cells. The release of LTBP-1 into the medium is decreased
by the inhibition of FLP activity. Gene-transfer mediated overex-
pression of LTBP-1 in glioma cell lines results in an increase
in TGF-b activity. Accordingly, Smad2 phosphorylation as an in-
tracellular marker of TGF-b activity is enhanced. Conversely,
LTBP-1 gene silencing reduces TGF-b activity and Smad2 phos-
phorylation without affecting TGF-b protein levels. Collectively,
we identify LTBP-1 as an important modulator of TGF-b activa-
tion in glioma cells, which may contribute to the malignant pheno-
type of these tumors.
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Transforming growth factor-b (TGF-b) is the prototype of a
superfamily of pleiotropic cytokines, which are fundamental
throughout development and in the maintenance of tissue homeo-
stasis in the normal and diseased state.1,2 TGF-b has also a major
role in the malignant phenotype of glioblastoma.3,4 The median
survival of patients affected by this tumor is below 12 months and
high TGF-b Smad activity may confer poor prognosis.5 Biological
effects of TGF-b modulating the course of glioblastoma may
include the induction of immunosuppression6 as well as its proper-
ties as a tumor progression factor promoting angiogenesis, inva-
sion and metastasis.7
Synthesis, release and activation of TGF-b constitute a complex
process. After removal of the signal peptide from pre-pro-TGF-b
and after homodimerization, further cleavage occurs through the
convertase family of endoproteases also termined as proprotein
convertases or furin-like proteases (FLP)8 to produce the C-termi-
nal mature peptide of 12.5 kDa and the N-terminal precursor re-
mainder, which is referred to as the latency-associated peptide
(LAP). This process may take place either within the cytosol9 or
in the extracellular space.10,11 After cleavage, mature TGF-b and
LAP remain noncovalently associated to form the small latent
complex (SLC). This interaction in the SLC conveys latency to
the receptor-interacting epitopes in the mature protein so that
TGF-b usually is secreted from cells in an inactive form.12 The
SLC can further covalently attach to latent TGF-b-binding pro-
teins (LTBP) to form large latent complexes (LLC).13
LTBPs are 120–220 kDa glycoproteins that are composed of
multiple epidermal growth factor (EGF)-like repeats and multiple
domains containing 8 cysteines—the 8-Cys or cysteine-rich (CR)
domains. The CR domains are unique to the ﬁbrillin/LTBP super-
family. Of the 4 LTBP isoforms, LTBP-1, LTBP-3 and to a lesser
degree, LTBP-4 covalently associate with the LAP of TGF-b via
their third CR domain.14 The other CR domains of LTBP may be
involved in matrix binding.15 The hinge sequences of LTBP-1 and
LTBP-2 are sensitive to proteolytic cleavage16,17 whereas those of
LTBP-3 and LTBP-4 are not.18 After secretion, LLC can bind to
the extracellular matrix (ECM), thereby targeting the latent TGF-
b complexes to speciﬁc storage sites as well as stabilizing latent
TGF-b complexes and regulating their activation in the extracellu-
lar space.19–21 For latent TGF-b to become activated, the mature
peptide needs to be released from LAP. The mechanisms by which
this occurs vary according to cell type and context.12 Apart from
the release from LAP, liberation of the LLC from the ECM may
promote local TGF-b activation, e.g., bone morphogenetic pro-
tein-1 (BMP-1) like metalloproteinases may control TGF-b acti-
vation by cleaving LTBP-1.22 Further, membrane type-1 matrix
metalloproteinase (MT1-MMP)-mediated proteolytic processing
of ECM-bound LTBP-1 has been identiﬁed as a mechanism to
release latent TGF-b from the subendothelial matrix.23 Once
active TGF-b is released from the ECM, it binds to TGF-b recep-
tor I and II heterodimers and induces them to directly activate
Abbreviations: 2-ME, 2-mercaptoethanol; AEBSF, 4-(2-ami-
noethyl)benzenesulfonylﬂuoride; BMP-1, bone morphogenetic
protein-1; BrdU, 5-bromo-2-deoxyuridine; CR, cysteine rich;
DEC-RVKR-CMK, decanoyl-Arg-Val-Lys-Arg-chloromethylke-
tone; ECM, extracellular matrix; FLP, furin-like protease; LAP,
latency-associated peptide; LLC, large latent complex; LTBP,
latent TGF-b-binding protein; MT1-MMP, membrane type-1
matrix metalloproteinase; pSmad2, phosphorylated Smad2; RT-
PCR, real-time PCR; rhTGF-b, recombinant human TGF-b; SLC,
small latent complex; TGF-b, transforming growth factor-b.
Grant sponsors: Jacqueline Seroussi Memorial Foundation for Cancer
Research, NCCR Neuro Zurich (Swiss National Science Foundation);
Grant sponsors: Landesstiftung Baden-W€urttemberg, Germany; Grant
number: P-LS-AS/HSPA7-12.
*Correspondence to: Department of Neurology, University Hospital
Zurich, Frauenklinikstrasse 26, CH-8091 Zurich, Switzerland.
Fax:141-44-2554507. E-mail: michael.weller@usz.ch
Received 8 December 2008; Accepted after revision 2 March 2009
DOI 10.1002/ijc.24443
Published online 19 March 2009 inWiley InterScience (www.interscience.
wiley.com).
Int. J. Cancer: 125, 530–540 (2009)
' 2009 UICC
Publication of the International Union Against Cancer
receptor-regulated Smads (R-Smads) such as Smad2 and Smad3
by phosphorylation. The R-Smads in turn form transcriptional
complexes with the common partner Smads (Co-Smads) to control
target gene expression.24 Signal transducer Smad proteins interact
with various transcription factors and abnormalities of these regu-
lators of TGF-b signaling may inﬂuence the progression of tumors
such as glioblastoma.25,26 Increased Smad2 phosphorylation has
recently been described as indicator of high TGF-b activity and as
a molecular marker of poor prognosis in glioma patients.5 Smad
signaling mediated by TGF-b is largely governed by the preceding
TGF-b activation process. We, therefore, focused this work on the
components of the TGF-b pathway located in the extracellular
matrix (ECM). We here identify LTBP-1 as an important player in
enhancing TGF-b activity and upregulating phoshorylated Smad2
(pSmad2) levels in human glioblastoma.
Material and methods
Cells and reagents
The human malignant glioma cell lines U87MG and T98G and
NIH-3T3 murine ﬁbroblasts were from ATCC (Rockville, MD).
LN-18, U138MG, LN-428, D247MG, LN-319, LNT-229, A172,
U251MG, U373MG and LN-308 cells were kindly provided by de
Tribolet (Lausanne, Switzerland). Primary glioblastoma cell cul-
tures, Tu132, Tu140, Tu323 and Tu325, were established from
freshly resected tumors and used during the ﬁrst passages. Trans-
fected mink lung epithelial cells (T-MLEC) were a kind gift of
D.B. Rifkin (New York, NY). The human SV-FHAS astrocytic
cell line was provided by D. Stanimirovic (Institute for Biological
Sciences, Ottawa, Canada). Stable LTBP-1 transfectants were
obtained by transfection using the constructs LTBP-1S-pEF-
IRES-P containing full-length human LTBP-1S cDNA and pEF-
IRES expression plasmids.27 The cells were maintained in DMEM
containing 10% fetal calf serum (Biochrom KG, Berlin, Germany)
supplemented with puromycin (1 lg/ml, Applichem, Darmstadt,
Germany) for the stable LTBP-1 transfectants and G418 (400 lg/
ml, Biochrom) for the T-MLEC. siRNA pools targeting LTBP-1,
TGF-b1 or TGF-b2 containing 4 selected siRNA duplexes each
with a modiﬁcation pattern that addresses off-target effects caused
by both strands (ON-TARGETplus SMARTpool) and the nontar-
geting control pool (ON-TARGETplus siCONTROL nontargeting
Pool) were purchased from Dharmacon (Lafayette, CO) and used
at 100 nM. The siRNA pool targeting LTBP-1 had the following
sequences: duplex sense sequence 50-CCGGGUUAUAAGCGGG
UUAUU-30, duplex sense sequence 50-GAACCAAACGUCUGCG
CAAUU-30, duplex sense sequence 50-GGAUUUAGGAUGAG
CCCGAUU, duplex sense sequence 50-GUAUAUGCUACGA
GGGCUAUU-30. The siRNA pool targeting TGF-b1 had the
duplex sense sequences 50-AUUGAGGGCUUUCGCCUUAUU-
30, 50-CCGAGAAGCGGUACCUGAAUU-30, 50-GCAGAGUA
CACACAGCAUAUU-30, 50-GTGACUAUCCACCUGCAAGA
UU-30. Sequences of the siRNA pool targeting TGF-b2 were
duplex sense sequences 50-GGAUUGAGCUAUAUCAGAUUU-
30, 50-CUGCGUGUCCCAAGAUUUAUU-30, 50-GAUGCGGC
CUAUUGCUUUAUU-30, and 50-GAGCAUGCCCGUAUUUAU
GUU-30. Stable and transient lipophilic transfection was per-
formed with Metafectene Pro (Biontex, Martinsried, Germany).
Plasmin from human plasma, the synthetic furin inhibitor deca-
noyl-Arg-Val-Lys-Arg-chloromethylketone (DEC-RVKR-CMK)
and the serine protease inhibitor 4-(2-Aminoethyl)benzenesulfo-
nylﬂuoride (AEBSF) were purchased from Calbiochem (Not-
tingham, UK). Recombinant human TGF-b1 (rhTGF-b1) and
recombinant human TGF-b2 (rhTGF-b2), antihuman LAP-TGF-
b1 polyclonal antibody (AF-246-NA) and monoclonal antihuman
LTBP-1 antibody (clone MAB388) were purchased from R&D
Systems (Minneapolis, MN). The polyclonal anti-LTBP-1 (ab39)
antibody was the kind gift of C. Heldin (Ludwig Institute for Can-
cer Research, Uppsala, Sweden). Rabbit polyclonal antibody to
TGF-b2 was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). TGF-b1, phospho-Smad2 (Ser465/467) (clone 138D4)
and Smad2 (clone 86F7) antibodies were purchased from Cell Sig-
naling Technology (Boston, MA). The antibody to GAPDH was
obtained from Chemicon (Temecula, CA).
Real-time PCR
Total RNA was prepared using the RNeasy system including
DNase treatment (Qiagen, Hilden, Germany) and transcribed
according to standard protocols. cDNA was prepared using the
Superscript RNase H2 Reverse Transcriptase (Invitrogen, Paisley,
UK) and random hexamers (Sigma). For RT-PCR, gene expres-
sion was measured in an ABI Prism 7000 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA) with SYBR Green
Master Mix (Eurogentec, Cologne, Germany) and primers (Sigma)
at optimized concentrations. GAPDH primers have been previ-
ously described.28 The sequences were as follows: TGF-b1, for-
ward 50-GCCCTGGACACCAACTATTG-30 (NM_000660.3,
nt 1702–1727), reverse 50-CGTGTCCAGGCTCCAAATG-30
(NM_000660.3, nt 1851–1869), TGF-b2, forward 5
0-AAGCTTA
CACTGTCCCTGCTGC-30 (NM_003238.1, nt 847–868), reverse
50-TGTGGAGGTGCCATCAATACCT-30 (NM_003228.1, nt
934–955), LTBP-1 L1S forward 50-CTTCCCCTGCCCGGTCT-
30 (NM 206943.1, nt 4161–4177; NM_000627.2, nt 3310–3327),
reverse 50-CTGCATCTTTATAGTTCTCACCACCA-30 (NM
206943.1, nt 4258–4279; NM_000627.2, nt 3408–3429), LTBP-
1L forward 50-GGTGCACCAAACCTAGCTGTG-30 (NM
206943.1, nt 554–574), reverse 50-ACAGGCTTTGCCCTTGG
TC-30 (NM 206943.1, nt 636–654) The conditions were 40 cycles,
95C/15 s, 60C/1 min. Standard curves were generated for each
gene and the ampliﬁcation was 90–100% efﬁcient. Relative quan-
tiﬁcation of gene expression was determined by comparison of
threshold values. All results were normalized to GAPDH and cal-
culated with the DCTT method for relative quantiﬁcation.
Immunoblot analysis
For the detection of proteins from cell lysates, cells were lysed
in radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris pH
8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS)
supplemented with 13 complete inhibitor mix (Roche Diagnos-
tics, Grenzach–Wyhlen, Germany), and phosphatase inhibitor
cocktails 1 and 2 (Sigma Aldrich, MO). Serum-free conditioned
media were concentrated with the centriplus centrifugal ﬁlter de-
vice YM-3 (3000-Da cut-off; Millipore, Eschborn, Germany).
ECM proteins were isolated essentially as described,29 including
the treatment with plasmin to solubilize the LTBP-1-containing
high molecular weight complexes. Protein levels were analyzed
by immunoblot using 20 lg of protein per lane mixed with
Laemmli buffer containing b-mercaptoethanol unless otherwise
indicated with the respective antibodies in the concentrations rec-
ommended by the manufacturer. Equal protein loading was ascer-
tained by Ponceau S staining. Visualization of protein bands was
accomplished using horseradish peroxidase-coupled secondary
antibodies (Sigma) and enhanced chemiluminescence (Perbio,
Bonn, Germany).
Cell proliferation assay
For the evaluation of cell proliferation by 5-bromo-2-deoxyuri-
dine (BrdU) incorporation, glioma cells were plated in 96-well
ﬂat-bottomed plates and 24 hr later treated with serum-free me-
dium for 24 hr. The cells were pulse-labeled with BrdU for the last
4 hr and then analyzed using the Amersham Cell Proliferation
Biotrak ELISA System (GE Healthcare, Buckinghamshire, UK)
according to the manufacturer’s recommendation.
TGF-b activity assay
T-MLEC, stably transfected with a luciferase gene driven by
TGF-b-responsive plasminogen activator inhibitor-1 promoter
sequences,30 were seeded in 96-well plates and allowed to adhere
over night. Serum-free medium supplemented with rhTGF-b1 for
the generation of a standard curve, glioma-conditioned medium
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for active TGF-b estimation or heat-treated (80C, 5 min) condi-
tioned medium for total TGF-b estimation were added to the T-
MLEC, which were harvested 18 hr later. Luciferase activity was
measured using the luciferase assay system (Promega, WI).
Human tissue specimens
We investigated 167 astrocytoma samples obtained from the tu-
mor bank of the Institute of Brain Research (Neuropathology),
University of Tuebingen, of patients who underwent surgical treat-
ment from 1993 to 2003 including 37 WHO grade II (293 ﬁbril-
lary, 53 gemistocytic, 33 protoplasmatic), 51 grade III anaplastic
astrocytomas and 79 glioblastomas (WHO grade IV). All speci-
mens corresponded to ﬁrst tumor diagnoses, and only primary
glioblastomas were included. Twenty-three autopsy cases of an
established normal brain bank were included for comparison. The
pathological diagnoses were conﬁrmed by at least 2 senior neuro-
pathologists. The histopathological typing and grading was done
according to the 2000 WHO criteria for tumors of the nervous sys-
tem. All specimens were ﬁxed in 4% formalin (pH 7.4), embedded
in parafﬁn and representative tissue samples were prepared as a
tissue microarray.31 The tissue microarray blocks were cut with a
microtome (3 lm thickness) and placed on SuperFrost Plus slides
(Microm International, Walldorf, Germany). All human material
was used in accordance to the policies of the local institutional
review board.
Immunohistochemistry
LTBP-1 immunohistochemistry was performed with a pretested
dilution of polyclonal rabbit antihuman LTBP-1 antibody (Ab 39).
All samples were deparafﬁnized and rehydrated. Immunohisto-
chemical tissue labeling was performed using the benchmark
immunohistochemistry system (Ventana, Strasbourg, France). A
standard protocol was used including a cell-conditioning pretreat-
ment. I-View-Inhibitor (Ventana) was applied for 4 min. LTBP-1
(Ab 39) was applied with an incubation time of 22 min. Slides
were incubated with an avidin and a biotin blocker for 4 min each
followed by 1 drop of biotinylated secondary antibody for 8 min.
For visualization, the sections were incubated with 1 drop of I-
View streptavidin-horse radish peroxidase for 8 min and then with
nickel-3,30-diaminobenzidine tetrahydrochloride /H2O2 for 8 min.
The sections were ﬁnally incubated with a copper enhancer (Ven-
tana) for 4 min, washed and counterstained with hematoxylin.
The staining of the ECM was evaluated with a scoring system,
0: no expression, 1: weak expression, 2: intermediate expression
or inhomogeneous strong expression, 3: homogeneous strong
expression. As a clear differentiation of extracellular and cytoplas-
mic staining is not possible in immunohistochemistry, both were
considered positive. The weak nuclear stain observed in single tis-
sues was not counted as positive. Evaluation of the immunohisto-
chemical staining and photographic documentation was performed
using an Olympus Vanox AHBT3 microscope.
Statistical analysis
For analysis of the score values in the immunohistochemical
studies, we used an analysis of variance (ANOVA) with subse-
quent Tukey HSD test, because the sample size in all groups was
sufﬁciently large for the central limit theorem to be applicable.
This theorem asserts that the distribution of means is asymptoti-
cally normal even if the individual variates have a non-normal dis-
tribution. The mean scores are given together with their 95% con-
ﬁdence intervals (CI). Signiﬁcant differences are illustrated (***p
< 0.001, **p < 0.01, *p < 0.05). JMP IN (Cary, NC) was used
for statistical analysis. For all other experiments showing quantita-
tive data, these are expressed as mean and SD. The experiments
shown were repeated 3 times with similar results. Analysis of sig-
niﬁcance was performed using the 2-tailed Student’s t-test (Excel,
Microsoft, Redmond, WA) (**p < 0.01, *p < 0.05, n.s.: not sig-
niﬁcant).
Results
Human malignant glioma cells express LTBP-1 in vitro
To assess whether glioma cells express LTBP-1, 12 established
glioma cell lines and 4 short-time primary cell cultures, designated
Tu132, Tu140, Tu323 and Tu325, were analyzed for LTBP-1
mRNA levels by real-time PCR. The use of different promoters
leads to 2 major LTBP-1 forms, long (L) and short (S), each
expressed in a temporally and spatially unique fashion.32 LTBP-
1L has a region of 346 amino acid residues (L-region) in its NH2-
terminal part which is not found in LTBP-1S.33 Thus, we differen-
tiated between LTBP-1L and LTBP-1S by the use of 2 primer
pairs, 1 detecting both the LTBP-1S and LTBP-1L form (LTBP-1
L1S) and 1 generating an amplicon of the sequence unique to the
LTBP-1L isoform (LTBP-1 L). LTBP-1 L1S mRNA was widely
expressed among the glioma cells. Only T98G cells expressed
very low mRNA levels. The speciﬁc ampliﬁcation of the LTBP-
1L region indicated a constant but minor proportion of LTBP-1L
mRNA whereas the LTBP-1S mRNA displayed considerable vari-
ation between the cell lines (Fig. 1a).
We next determined LTBP-1 protein levels by immunoblot.
LTBP-1 was barely detectable in whole cell extracts containing
cell surface proteins (data not shown). Glioma cells as well as nor-
mal human astrocytes have been reported to produce an ECM
in vitro.34 To resolve the question whether LTBP-1 is associated
with the ECM, we analyzed by immunoblot the proteins solubi-
lized from the ECM by plasmin. The experiments revealed that
LTBP-1 is, indeed, a component of the glioma cell ECM. LN-18,
U138MG, U87MG and LN-428 cells with high total LTBP-1
mRNA levels had the highest levels of LTBP-1 protein in the
ECM. Plasmin truncates LTBP-1 at the hinge region resulting in a
120 kDa fragment common to LTBP-1L and LTBP-1S.35 A frag-
ment of that size was detected in the ECM of most of the glioma
cell lines examined except in T98G and LNT-229 cells, where we
could barely detect LTBP-1 (Fig. 1b). The cells released truncated
forms of LTBP-1 into the medium with the major size around 190
kDa and with variations of the size of the truncated forms between
the cell lines, presumably depending on which endogenous pro-
teinases cleave and liberate LTBP-1 from the ECM (Fig. 1c). In
parallel, the levels of TGF-b1 and TGF-b2 in the conditioned
media of the same panel of glioma cells were determined. LTBP-1
protein levels detected in the ECM (Fig. 1b) and conditioned
media (Fig. 1c) roughly correlated whereas there was no overt,
apparent correlation of TGF-b1 or TGF-b2 protein levels with
LTBP-1 protein levels.
Expression of LTBP-1 increases from grade II to
grade IV in vivo
To validate our observations, we analyzed LTBP-1 expression
in human gliomas in vivo. Parafﬁn-embedded tissue sections were
immunostained with the LTBP-1 antibody ab39. The evaluation of
LTBP-1 expression in astrocytomas grade II–IV and normal fron-
tal brain white matter revealed very low levels in normal brain
white matter (mean score 0.15 (CI 0–0.61)) with 85% of cases
showing no expression and 15% only weak expression in a diffuse
staining pattern. Although slightly higher, the levels in grade II
tumors (mean score 0.56 (CI 0.28–0.84)) were not statistically dif-
ferent from normal brain. Expression in high grade astrocytomas
WHO III (mean score 1.2 (CI 0.94–1.45) and IV (mean score 1.34
(CI 1.13–1.56), was signiﬁcantly higher than grade II (II to III p 5
0.001, II to IV p < 0.0001). Approximately 60% of grade II, 20%
of grade III and 10% of grade IV tumors were classiﬁed with score
0 for no detectable LTBP-1 (Fig. 2). These results represent an
integration of extracellular and cytoplasmic staining of the respec-
tive normal brain or tumor cells. Additionally, LTBP-1 staining
was observed within blood vessels in a diffuse pattern and local-
ized to small cells without nuclei, most likely representing plate-
lets (data not shown). Indeed, platelets have been reported to
secrete high amounts of LTBP-1-LAP-TGF-b1 complexes.
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Release of LLC into cell conditioned medium depends
on FLP-mediated LTBP-1 cleavage
TGF-b is secreted as part of LLC (Fig. 3a) by most cell types,
although some cells secrete free forms of SLC, too.37 Secretion of
TGF-b1,TGF-b2 and TGF-b3 in high molecular weight LTBP-1
containing complexes has previously been reported for a human
glioblastoma cell line.38 We chose LNT-229 with relatively low
constitutive LTBP-1, TGF-b1 and TGF-b2 levels and LN-308 with
higher constitutive LTBP-1, TGF-b1 and TGF-b2 levels (Fig. 1) to
analyze the mode of TGF-b secretion in the conditioned media by
immunoblot. We compared nonreducing conditions with intact di-
sulﬁde bonds and reducing conditions with 2-mercaptoethanol (2-
ME) treatment (Fig. 3b). Under non-reducing conditions, probing
with anti-LAP-TGF-b1 antibody speciﬁc for the N-terminal region
of pro-TGF-b1 (lane 5 for LNT-229 and lane 7 for LN-308)
detected a protein band migrating with the same velocity as a por-
tion of the protein complex detected by the LTBP-1 antibody (lane
1 for LNT-229 and lane 3 for LN-308). This band in lanes 5 and 7
at a molecular weight >260 kDa presumably represents LLC con-
sisting of LTBP isoforms linked to LAP-TGF-b1 (190 kDa LTBP-
1 plus disulﬁde-linked LAP-TGF-b1 dimer of 70 kDa) or of LTBP
isoforms linked to pro-TGF-b1 (190 kDa LTBP-1 plus disulﬁde-
linked proTGF-b1 dimer of 100 kDa). Probing with C-terminal
epitope speciﬁc TGF-b1 antibody (lanes 9 and 11) and TGF-b2
antibody (lanes 13 and 15) under nonreducing conditions
detected protein complexes with a molecular weight higher than
260 kDa, which were not detected under reducing conditions
with the same antibodies (lanes 10 and 12 for TGF-b1 and lanes
14 and 16 for TGF-b2). As the C-terminal-speciﬁc TGF-b1 and
TGF-b2 antibodies recognize both the uncleaved pro-TGF-b and
FIGURE 1 – Human malignant glioma cells express LTBP-1 in vitro. (a) LTBP-1L and LTBP-1L1S (representative for the L and S form)
mRNA levels were analyzed by real-time PCR using GAPDH as a reference. (b) The polypeptides of the ECM, prepared from the glioma cells,
were solubilized by plasmin, separated by SDS-PAGE and assessed for LTBP-1 by immunoblot. (c) The respective glioma cells were incubated
in serum-free medium for 48 hr. Truncated LTBP-1, LAP-TGF-b1 and TGF-b2 proteins were detected in the conditioned media by immunoblot.
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the mature TGF-b forms (lanes 10, 12, 16), this conﬁrms that
some pro-TGF-b is secreted unprocessed and stored in LLC in
glioma cells.
The proteolytic processing of LTBP-1 from the ECM has been
attributed recently also to BMP-122 or MT1-MMP.23 Because of
their TGF-b activating properties in gliomas11 we are interested
in FLP as potential therapeutic targets for the experimental ther-
apy of gliomas.11 It has been reported that both the activation of
BMP-139 and the activation of MT1-MMP40 involve the action
of a furin proteinase. Indeed, exposure to the speciﬁc furin inhib-
itor DEC-RVKR-CMK resulted in decreased levels of truncated
LTBP-1 in the media in a concentration-dependent manner along
with an increase of LTBP-1 protein in the ECM. As a control,
we included AEBSF, a serine protease inhibitor, which has been
reported to inhibit the release of truncated LTBP-1 and LL-TGF-
b41 by a yet unresolved mechanism. As reported previously,11
the furin inhibitor inhibited the processing of TGF-b as demon-
strated by the accumulation of pro-TGF-b1 and the decrease of
LAP-TGF-b1 as detected by the N-terminus-speciﬁc LAP-TGF-
b1 antibody (Fig. 3c).
TGF-b stimulation inﬂuences LTBP-1 expression
in a cell type-speciﬁc manner
We chose the LNT-229 and LN-308 glioma cell lines to assess
whether siRNA-mediated depletion of endogenous TGF-b1 or
TGF-b2 levels or stimulation with rhTGF-b1 or rhTGF-b2 inﬂu-
ence LTBP-1 expression (Figs. 4a and 4b). Short-term stimulation
for 7 hr with rhTGF-b1 or rhTGF-b2 did not alter the mRNA lev-
els of LTBP-1 in either cell line (data not shown). However, pro-
longed exposure to rhTGF-b1 or rhTGF-b2 for 24 and 48 hr led to
an increase of LTBP-1, TGF-b1 and TGF-b2 mRNA in LNT-229
cells. For example, 45 hr treatment with rhTGF-b1 led to a 18-fold
increase of TGF-b1 and a 7-fold increase of LTBP-1 and TGF-b2
mRNA levels, similar results were achieved for stimulation with 5
ng/ml rhTGF-b2 for 45 hr. Stimulation of LN-308 cells with
rhTGF-b1 or rhTGF-b2 increased TGF-b1 mRNA levels, but nei-
ther signiﬁcantly inﬂuenced TGF-b2 nor LTBP-1 mRNA levels
(Fig. 4a). Immunoblotting revealed a distinct induction of trun-
cated LTBP-1 protein in LNT-229 cells after stimulation with
TGF-b1 or TGF-b2 for 45 hr. This induction was not observed in
LN-308 cells.
SiRNA-mediated depletion of endogenous TGF-b1 or TGF-b2
levels in LNT-229 and LN-308 cells at 30, 45 (data not shown) or
60 hr post transfection did not signiﬁcantly alter LTBP-1 mRNA
(Fig. 4a) or protein levels (Fig. 4b). Unexpectedly, speciﬁc knock-
down of TGF-b1 in LN-308 cells also reduced TGF-b2 protein
levels suggesting a crosstalk between the TGF-b1 and TGF-b2 sig-
naling pathways in these cells. Inhibition of the Smad2 signaling
cascade by the TGF-b receptor I kinase inhibitor SD-20842 did not
strongly inﬂuence LTBP-1 mRNA or protein expression at 7, 40
(data not shown) or 60 hr, but decreased TGF-b1 and TGF-b2 lev-
els in LN-308 cells, which release more TGF-b1 and TGF-b2 than
LNT-229 cells.
Gene transfer-mediated overexpression of LTBP-1 in glioma cell
lines increases both autocrine and paracrine TGF-b activity
We generated transfectant pools of 2 glioma cell lines by plas-
mid-mediated gene transfer. Both pools were conﬁrmed to overex-
press LTBP-1 at mRNA (Fig. 5a) and protein level in the ECM
FIGURE 2 – Human gliomas express LTBP-1 in vivo. (a), (c–f) LTBP-1 immunoreactivity in parafﬁn-embedded human gliomas and in normal
brain tissue immunostained with LTBP-1 antibody (ab39). (a) Depiction of scoring system (0: no expression, 1: weak expression, 2: intermediate
expression or inhomogeneous strong expression, 3: homogeneous strong expression). (b) LTBP-1 expression levels were quantiﬁed according to
the scoring system and the respective mean score and 95% conﬁdence intervals are shown. (c–f) Representative photomicrographs of parafﬁn-
embedded tissue sections of (c) diffuse astrocytoma WHO grade II (illustrated score 0), (d) anaplastic astrocytoma WHO grade III (illustrated
score 2), (e) glioblastoma WHO grade IV (illustrated score 3, note weak immunostaining in pseudopalisading necrosis) (f) normal brain (illus-
trated score 0). Magniﬁcation for (a), (c), (d), (f)3200, for (e) 3100, scale bar 100 lm.
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and in the conditioned media (Fig. 5b). LNT-229/LTBP-1-pEF-
IRES transfectants showed 65-fold increased mRNA levels of
LTBP-1 and also increased levels of TGF-b1 (6-fold), and TGF-
b2 mRNA (2-fold). In line with these results, TGF-b1 and TGF-b2
protein levels were also upregulated in LNT-229/LTBP-1 cells
(Fig. 5b). In contrast, LN-308/LTBP-1-pEF-IRES transfectants
which showed comparable LTBP-1 mRNA overexpression did not
display signiﬁcant changes in TGF-b1 or TGF-b2 mRNA levels
(Fig. 5a). To analyze whether overexpression of LTBP-1 inﬂuen-
ces downstream signaling by TGF-b, the respective glioma whole
cell lysates were subjected to immunoblot analysis. LNT-229/
LTBP-1 cells displayed elevated Smad2 phosphorylation levels
and decreased total Smad2 protein levels whereas LN-308/LTBP-
1 cells did not (Fig. 5c). As the majority of latent TGF-b is
released by heat treatment, the activity of the heat-treated, condi-
tioned medium reﬂects the amount of total TGF-b in the condi-
tioned medium which is consistent with the elevated protein secre-
tion in the LNT-229/LTBP-1 cells (Fig. 5b). Accordingly, TGF-b
activity was increased in the native and in the heat-activated con-
ditioned media of LNT-229/LTBP-1 cells (Fig. 5d). In contrast to
the protein data (Fig. 5b), the heat-activated conditioned media of
the LN-308/LTBP-1 transfectants displayed also an increase of
approximately 20% in total TGF-b activity. TGF-ß activity in the
native conditioned media of LN-308/LTBP-1 cells was elevated
by 40% (Fig. 5d). That the moderate increase in TGF-b activity
did not translate into enhanced Smad2 phosphorylation in LN-308
cells is probably related to the fact that constitutive Smad2 phos-
phorylation is already prominent in this cell line. To assess the
FIGURE 3 – LLC is secreted into the conditioned medium of gliomas and LTBP-1 cleavage is dependent on FLP. (a) A schematic graphic of
the LLC is depicted modiﬁed from Ref. 35 (see text for details). (b) The glioma cell lines LNT-229 and LN-308 were incubated in serum-free
medium for 48 hr. Detection of truncated LTBP-1, LAP-TGF-b1, TGF-b1 and TGF-b2 in the conditioned media by immunoblot was performed
under non-reducing (without 2-mercaptoethanol, 2-ME) or reducing conditions (with 2-ME) as indicated. (c) LN-308 cells were cultured with
serum-free medium in the presence of the furin inhibitor DEC-RVKR-CMK at 15, 30 or 60 lM or AEBSF at 150 lM for 48 hr. Truncated
LTBP-1 and LAP-TGF-b1 were detected in the conditioned media and LTBP-1 in the ECM by immunoblot.
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LTBP-1 effect on the proliferation of these cell lines, we per-
formed BrdU incorporation assays. There was an elevation of
BrdU incorporation by 50% in LNT-229/LTBP-1 cells and a
decrease by 23% in LN-308/LTBP-1 cells (Fig. 5e).
siRNA-mediated downregulation of LTBP-1 results both
in autocrine and paracrine reduction of TGF-b
activity in LN-308 cells
Next, we examined the effects of LTBP-1 gene silencing by
small interference RNA (siRNA) in LN-308 cells (Fig. 6). We
conducted a time course experiment after the introduction of the
siRNA. The maximal reduction of message was achieved at 48 hr
post transfection with 12% of LTBP-1 mRNA left in the cells
treated with LTBP-1 siRNA (Fig. 6a). LTBP-1 protein levels in
the ECM extracts and in the conditioned media (Fig. 6b) were
equally downregulated at 60 hr post transfection. LTBP-1 gene
silencing did not substantially inﬂuence TGF-b mRNA transcrip-
tion (Fig. 6a) or TGF-b release into the conditioned medium (Fig.
6b). Importantly, we observed a strong reduction of Smad2 phos-
phorylation levels that was most prominent at 60 hr post transfec-
tion (Fig. 6c). Accordingly, the luciferase-based TGF-b activity
assay revealed a reduction of TGF-b activity to 50% in the native
conditioned medium of the LTBP-1-depleted cells 60 hr post
transfection. In contrast, TGF-b activity in the heat-activated con-
ditioned media of the LTBP-1 knockdown did not differ signiﬁ-
cantly from the respective control (Fig. 6d). As controls, we
included conditioned medium from LN-308 cells that were treated
with siRNA pools for TGF-b1 or TGF-b2. At 60 hr post transfec-
tion, TGF-b activity was reduced both with TGF-b1 and TGF-b2
gene silencing in both native (latent) and heat-activated (total)
conditioned media (Fig. 6d). We performed BrdU incorporation
assays to determine whether silencing of LTBP-1, TGF-b1 or
TGF-b2 expression altered LN-308 cell proliferation under the
experimental conditions reported here. There was a 35% increase
in the proliferation of LN-308/LTBP-1si cells determined at
24–60 hr post transfection. In line, TGF-b1 and TGF-b2 gene
silencing in LN-308 glioma cells led to an increase in BrdU incor-
poration of 59 and 53% (Fig. 6e).
Discussion
TGF-b is a key molecule attributed a major role in the malig-
nant phenotype of various types of cancer.43 Depending on the
stage and type of cancer, TGF-b mediates angiogenesis, motility
or immunosuppression or, as in malignant gliomas, a combination
thereof. The inﬁltration of malignant gliomas by lymphocytes and
macrophages conﬁrms a potential for lymphocyte homing and
generation of antitumor responses.3 However, clinically, the
immune system fails to mount an effective immune response
against these tumors. This has been attributed to the immune-priv-
ileged status of the brain conferred by the blood brain barrier and
to the local release by glioma cells of soluble immunosuppressive
factors such as TGF-b.3,44 Indeed, TGF-b2 has been detected in
tumor cyst and in the cerebrospinal ﬂuid of patients with glio-
mas.45,46 The concentrations of TGF-b1 and TGF-b2 are elevated
in the plasma of patients with glioblastomas.47 The latter study
described, indeed, a statistically signiﬁcant elevation of active and
latent TGF-b1 and TGF-b2 in glioblastoma patient plasma prior to
surgery. Thus, elucidation of the mechanisms and molecules
involved in TGF-b activation in glioblastomas is of paramount
FIGURE 4 – TGF-b stimulation inﬂuences LTBP-1 expression in a cell type-speciﬁc manner, whereas siRNA-mediated knockdown of TGF-
b1 or TGF-b2 as well as inhibition of TGF-b-signaling do not regulate LTBP-1 levels. (a) Relative changes of LTBP-1, TGF-b1, and TGF-b2
mRNA levels in LNT-229 and LN-308 cells were assessed after exposure to rhTGF-b1 or rhTGF-b2 (5 ng/ml) for 45 hr, SD-208 (1 lM) for 60
hr or after siRNA-mediated knockdown of TGF-b1 and TGF-b2 60 hr post transfection respectively. Expression ratios relative to the respective
control or untreated cells are depicted. Immunoblot boxes represent pSmad2, Smad2 and GAPDH protein levels (lysates) to conﬁrm effective
inhibition of Smad2 phosphorylation by SD-208. (b) LTBP-1, TGF-b1 and TGF-b2 (conditioned media) were detected by immunoblot at the
same time points as in (a).
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importance when designing experimental strategies of antagoniz-
ing the biological effects of TGF-b.
Human glioblastoma cell lines secrete TGF-b in different forms
of LLC covalently associated with LTBP-1 and other not yet
identiﬁed components of similar size as well as in SLC contain-
ing only LAP.38 We characterize LTBP-1 as an important player
in the process of TGF-b activation in glioma cells. We report the
expression of LTBP-1 in long-term glioma cell lines as well as
in primary ex vivo glioblastoma cells (Fig. 1). LTBP-1 expres-
sion in human brain tumors signiﬁcantly increases with WHO
grade (Fig. 2). However, in vitro, high levels of LTBP-1 protein
were not tightly linked to high levels of active TGF-b1 or TGF-
b2 (Fig. 1c). As reported previously,
38 TGF-b1 and TGF-b2 are
detected in disulﬁde-linked high molecular weight complexes in
the conditioned medium of glioma cells (Fig. 3b). FLP are
released by glioma cells and process TGF-b in the extracellular
space.11 Release of LLC and the truncation of LTBP-1 are also
regulated proteolytically and presumably part of a proteolytic
cascade. We ﬁnd that the FLP activity is also involved in the
proteolytic processing of LTBP-1 and its release in the condi-
tioned medium (Fig. 3c). As neither the speciﬁc knockdown of
TGF-b1 or TGF-b2 nor the disruption of TGF-b signaling by
SD-208 changed LTBP-1 levels in the conditioned media, the
effect achieved by the furin inhibitor could not be attributed to
the depletion of mature TGF-b by the furin inhibitor (Figs. 4a
and 4b).
Exposure of LNT-229 cells, which exhibit low levels of LTBP-
1, TGF-b1 and TGF-b2 protein, to TGF-b1 or TGF-b2 induced
LTBP-1 mRNA (Fig. 4a) and increased LTBP-1 protein in the me-
dium (Fig. 4b). In contrast, LTBP-1 expression in LN-308 cells,
FIGURE 5 – LTBP-1 overexpression increases TGF-b activation in malignant glioma cell lines. (a) LTBP-1 mRNA overexpression in LNT-
229/LTBP1 and LN-308/LTBP1 cells normalized to LNT-229/LN-308 pEF-IRES control cells as well as TGF-b1 and TGF-b2 mRNA levels
were assessed by RT-PCR. (b) LTBP-1 protein levels in the ECM of the respective cell lines solubilized by plasmin were detected by immuno-
blot. LTBP-1, TGF-b1 and TGF-b2 protein levels were assessed in the conditioned media of the LNT-229/LN-308 pEF-IRES control and re-
spective LTBP-1 cells by immunoblot. (c) Whole cell lysates of LNT-229 pEF-IRES, LNT-229/LTBP-1, LN-308 pEF-IRES and LN-308/
LTBP-1 transfectants, serum-starved for 48 hr, were assessed for pSmad2 and total Smad2 by immunoblot using GAPDH as a reference. (d)
Conditioned media from LNT-229/LN-308 pEF-IRES control or the respective LTBP-1-pEF-IRES overexpressing cells were added to TMLEC-
TGF-b-reporter cells without or with heat activation (80C, 5 min) for detection of active or total TGF-b. Data sets represent relative expression
ratios of LTBP-1-overexpressing cells versus control-transfected cells. (e) LNT-229/LN-308 pEF-IRES control and the respective LTBP-1-pEF-
IRES overexpressing cells were assessed for proliferation by BrdU-incorporation. Proliferative capacity of the LTPB-1 overexpressing cells nor-
malized to the results of the respective control cells is presented.
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which show high constitutive TGF-b1 and TGF-b2 protein levels,
was not further inducible by exogenous TGF-b. Similarly, forced-
expression of LTBP-1 by stable plasmid-mediated gene transfer
led to increased TGF-b1 and TGF-b2 mRNA and protein levels in
LNT-229/LTBP-1, but not in LN-308/LTBP-1 cells (Figs. 5a and
5b). There was increased Smad2 phosphorylation in LNT-229/
LTBP-1 cells, but not in LN-308/LTBP-1 cells (Fig. 5c). Yet,
TGF-b activity was increased in LNT-229/LTBP1 and in LN-308/
LTBP-1 cells (Fig. 5d). For the LNT-229/LTBP-1 cells, this corre-
sponds to elevated total TGF-b1 and TGF-b2 levels (Fig. 4b). Al-
together, these data are consistent with a positive feedback loop
between LTBP-1 expression and TGF-b bioavailability in glioma
cells with low endogenous TGF-b levels such as LNT-229 cells.
When endogenous TGF-b is constitutively high, as in LN-308
cells, the main role of LTBP-1 is to activate TGF-b and not to reg-
ulate its expression.
Importantly, we observed an increase of activated TGF-b in the
conditioned media of LNT-229/LTBP1 and LN-308/LTBP1 cells
(Fig. 5d). Despite producing the same protein levels of TGF-b1
and TGF-b2 as controls (Fig. 5b), LN-308/LTBP-1 cells exhibited
increased TGF-b activation. LTBP-1 depletion in LN-308 cells
with abundant TGF-b expression led to minor changes in TGF-b1
and TGF-b2 mRNA levels that did not translate into altered pro-
tein levels (Figs. 6a and 6b). Yet, LTBP-1 depletion strongly
reduced Smad2 phosphorylation levels (Fig. 6c) and, accordingly,
TGF-b activity was decreased by 50% for the native supernatants
(Fig. 6d). Of note, the LTBP-1 knockdown in LNT-229 cells did
not change their phenotype in paracrine or autocrine TGF-b sig-
naling what may be due to their low endogenous levels of TGF-b1
and TGF-b2 (data not shown).
LTBP-1 associates with TGF-ß in complex with its propeptide
and targets TGF-b to speciﬁc extracellular structures.12,48 In epi-
thelial cells, LTBP-1 needs to be matrix-bound for amb6-integ-
rin-mediated activation.49 In contrast, protease-mediated activa-
tion has been described as a multi-step process in liberating
active TGF-b from the ECM. The ﬁrst step may involve the
release of the latent complex from the ECM by proteolytic
cleavage of LTBP-1 at protease-sensitive sites resulting in trun-
cated LTBP-1 in association with SLC.20,41 The second step,
activation of latent TGF-b, liberates TGF-b from its noncovalent
complex with LAP mediated by the interaction with proteases,
integrins or thrombospondin in cell type-speciﬁc ways.12,20 Here,
we report a role for glioma cell-derived LTBP-1 in the process
of autocrine and paracrine TGF-b activation. FLP are not only
FIGURE 6 – siRNA-mediated inhibition of LTBP-1 expression reduces TGF-b activation and autocrine Smad signaling in LN-308 cells. (a)
and (b) LN-308 cells treated with non-targeting control or LTBP-1 siRNA pool were assessed for LTBP-1, TGF-b1 or TGF-b2 mRNA levels by
RT-PCR at 36, 48 or 60 hr post transfection (a) and by immunoblot of the ECM and the conditioned media at 60 hr post transfection (b). (c)
Whole cell lysates of the LN-308 control or LTBP-1si cells which had been serum-starved from 12 hr post transfection were assessed for
pSmad2 and Smad2 by immunoblot using GAPDH as a reference. Lysates were prepared 36, 48 or 60 hr post transfection. (d) Conditioned
media from LN-308 non-targeting control or LN-308 LTBP-1si, TGF-b1si or TGF-b2si cells (60 hr post transfection) were analyzed by
TMLEC-TGF-b-reporter cell assay without or with heat activation (80C, 5 min) for detection of active or total TGF-b. Data were normalized
to the results of the respective control cells. (e) LN-308 cells were transfected with non-targeting siRNA or siRNA targeting LTBP-1, TGF-b1
or TGF-b2. 24 hr later equal numbers of the cells were plated and the proliferative capacity until 60 hr post transfection was determined by BrdU
incorporation and normalized to the results of the respective control transfected cells. SiRNA knockdown efﬁciency on mRNA levels is pre-
sented in Figure 6a for the LTBP-1 siRNA and Figure 4a for the TGF-b1 or TGF-b2 siRNA.
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involved in the processing of TGF-b,11 but also in the proteo-
lytic truncation of LTBP-1 in glioma cells, underscoring their
role in the process of TGF-b activation. Further studies on the
mechanism of TGF-b activation might be of considerable signif-
icance in providing therapeutic options for the treatment of
malignant tumors such as glioblastomas which are characterized
by a dependence of their malignant phenotype on high TGF-b
activity.
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